Hydroxyurea is an antineoplastic and immunosuppressive agent belonging to the hydrazine class, primarily indicated for the treatment of sickle cell disease, essential thrombocythemia, chronic myelogenous… Read more
Hydroxyurea is an antineoplastic and immunosuppressive agent belonging to the hydrazine class, primarily indicated for the treatment of sickle cell disease, essential thrombocythemia, chronic myelogenous leukemia, and cervical cancer. It functions by inhibiting ribonucleotide reductase, effectively suppressing DNA synthesis and cell division within these conditions. To support rigorous pharmaceutical development and regulatory compliance, this category provides high-quality reference standards of the active pharmaceutical ingredient, alongside its degradation products and impurities. These compounds, including stable isotope labelled analogues, are critical for accurate impurity profiling and method validation. Pharmaceutical laboratories utilize these materials to ensure the precision of analytical testing, enabling the identification and quantification of related substances and metabolites during quality control procedures, thereby maintaining the consistency and safety profiles of drug formulations throughout their lifecycle.